HCA Healthcare's Health Check-Up Reveals Opportunity As Earnings Near

HCA Healthcare has delivered strong multi-year growth in revenue, profits, and cash flow, outperforming the S&P 500 since initial ‘buy' ratings. I maintain a soft ‘buy' on HCA, citing continued operational growth, robust share buybacks, and manageable leverage despite approaching fair value relative to peers. Management projects 2026 revenue of $76.5–$80 billion, EBITDA growth, and ongoing operational improvements, though regulatory and reimbursement risks remain.